Trial Outcomes & Findings for Study of the Effects of High Dose Aflibercept Injected Into the Eye of Patients With an Age-related Disorder That Causes Loss of Vision Due to Growth of Abnormal Blood Vessels at the Back of the Eye (NCT NCT04423718)

Last Updated: 2025-08-29

Results Overview

Visual function of the study eye was assessed at a distance of 4 meters using the ETDRS BCVA letter score. BCVA scale range is 0 (worst) to 100 (best).

Recruitment status

COMPLETED

Study phase

PHASE3

Target enrollment

1011 participants

Primary outcome timeframe

At baseline and Week 48

Results posted on

2025-08-29

Participant Flow

The study was conducted at 251 centers in 27 countries/regions with first participant first visit on 20-AUG-2020 and last participant last visit (Week 156) on 07-Aug-2024.

Overall, 1395 participants were screened, of whom 383 participants did not complete screening, 1 participant was randomized in error although he/she did not complete screening and had withdrawn consent. A total of 1011 participants were randomized in nearly equal numbers to 1 of the 3 treatment groups.

Participant milestones

Participant milestones
Measure	Aflibercept 2q8 (Week 0-96) / HD (up to Week 156) Participants enrolled in main study received aflibercept 2 mg administered every 8 weeks after 3 initial injections at 4-week intervals up to 96 weeks. Participants enrolled in the extension originally assigned to 2q8 in main study and switched to high dose aflibercept starting at Week 96.	Aflibercep HDq12 (Week 0-156) Participants enrolled in main study received high dose (HD) aflibercept administered every 12 weeks after 3 initial injections at 4-week intervals, up to 96 weeks. Participants enrolled in the extension continued with HD aflibercept at their latest dosing interval at Week 96.	Aflibercept HDq16 (Week 0-156) Participants enrolled in main study received high dose (HD) aflibercept administered every 16 weeks after 3 initial injections at 4-week intervals, up to 96 weeks. Participants enrolled in the extension continued with HD aflibercept at their latest dosing interval at Week 96.
Main Study STARTED	336	335	338
Main Study COMPLETED	286	291	292
Main Study NOT COMPLETED	50	44	46
Extension Phase STARTED	208	210	207
Extension Phase Treated	208	210	207
Extension Phase COMPLETED	187	186	191
Extension Phase NOT COMPLETED	21	24	16

Reasons for withdrawal

Reasons for withdrawal
Measure	Aflibercept 2q8 (Week 0-96) / HD (up to Week 156) Participants enrolled in main study received aflibercept 2 mg administered every 8 weeks after 3 initial injections at 4-week intervals up to 96 weeks. Participants enrolled in the extension originally assigned to 2q8 in main study and switched to high dose aflibercept starting at Week 96.	Aflibercep HDq12 (Week 0-156) Participants enrolled in main study received high dose (HD) aflibercept administered every 12 weeks after 3 initial injections at 4-week intervals, up to 96 weeks. Participants enrolled in the extension continued with HD aflibercept at their latest dosing interval at Week 96.	Aflibercept HDq16 (Week 0-156) Participants enrolled in main study received high dose (HD) aflibercept administered every 16 weeks after 3 initial injections at 4-week intervals, up to 96 weeks. Participants enrolled in the extension continued with HD aflibercept at their latest dosing interval at Week 96.
Main Study Adverse Event	9	5	8
Main Study Physician Decision	3	3	2
Main Study Protocol Violation	0	0	1
Main Study Lost to Follow-up	3	3	4
Main Study Lack of Efficacy	2	1	0
Main Study Withdrawal by Subject	14	20	20
Main Study Death	10	7	7
Main Study COVID-19 pandemic	2	2	2
Main Study Other	7	3	2
Extension Phase Other	1	0	0
Extension Phase Logistical problems	0	1	1
Extension Phase Physician Decision	1	0	1
Extension Phase Lack of Efficacy	2	0	1
Extension Phase Lost to Follow-up	0	2	3
Extension Phase Adverse Event	2	3	1
Extension Phase Death	4	7	2
Extension Phase Withdrawal by Subject	11	11	7

Baseline Characteristics

Full analysis set, except 1 participant who did not have a valid baseline measure.

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure	Aflibercept 2q8 n=336 Participants Participants received aflibercept 2 mg administered every 8 weeks after 3 initial injections at 4-week intervals, up to 96 weeks.	Aflibercept HDq12 n=335 Participants Participants received high dose (HD) aflibercept administered every 12 weeks after 3 initial injections at 4-week intervals, up to 96 weeks. Participants in this group can have their treatment intervals adjusted according to pre-specified dose regimen modification (DRM) criteria	Aflibercept HDq16 n=338 Participants Participants received high dose (HD) aflibercept administered every 16 weeks after 3 initial injections at 4-week intervals, up to 96 weeks. Participants in this group can have their treatment intervals adjusted according to pre-specified DRM criteria	Total n=1009 Participants Total of all reporting groups
Age, Continuous	74.2 Years STANDARD_DEVIATION 8.8 • n=336 Participants	74.7 Years STANDARD_DEVIATION 7.9 • n=335 Participants	74.5 Years STANDARD_DEVIATION 8.5 • n=338 Participants	74.5 Years STANDARD_DEVIATION 8.4 • n=1009 Participants
Sex: Female, Male Female	188 Participants n=336 Participants	182 Participants n=335 Participants	180 Participants n=338 Participants	550 Participants n=1009 Participants
Sex: Female, Male Male	148 Participants n=336 Participants	153 Participants n=335 Participants	158 Participants n=338 Participants	459 Participants n=1009 Participants
Ethnicity (NIH/OMB) Hispanic or Latino	12 Participants n=336 Participants	7 Participants n=335 Participants	9 Participants n=338 Participants	28 Participants n=1009 Participants
Ethnicity (NIH/OMB) Not Hispanic or Latino	322 Participants n=336 Participants	322 Participants n=335 Participants	326 Participants n=338 Participants	970 Participants n=1009 Participants
Ethnicity (NIH/OMB) Unknown or Not Reported	2 Participants n=336 Participants	6 Participants n=335 Participants	3 Participants n=338 Participants	11 Participants n=1009 Participants
Baseline BCVA measured by the ETDRS letter score	58.9 scores on a scale STANDARD_DEVIATION 14.0 • n=336 Participants	59.9 scores on a scale STANDARD_DEVIATION 13.4 • n=335 Participants	60.0 scores on a scale STANDARD_DEVIATION 12.4 • n=338 Participants	59.6 scores on a scale STANDARD_DEVIATION 13.3 • n=1009 Participants
Baseline choroidal neovascularization (CNV) size	6.3593 mm² STANDARD_DEVIATION 5.0394 • n=336 Participants • Full analysis set, except 1 participant who did not have a valid baseline measure.	5.9768 mm² STANDARD_DEVIATION 4.8306 • n=335 Participants • Full analysis set, except 1 participant who did not have a valid baseline measure.	6.5459 mm² STANDARD_DEVIATION 5.5315 • n=337 Participants • Full analysis set, except 1 participant who did not have a valid baseline measure.	6.2946 mm² STANDARD_DEVIATION 5.1433 • n=1008 Participants • Full analysis set, except 1 participant who did not have a valid baseline measure.
Baseline total lesion area	6.8647 mm² STANDARD_DEVIATION 5.4145 • n=336 Participants • Full analysis set, except 2 participants who did not have a valid baseline measure.	6.3820 mm² STANDARD_DEVIATION 5.0664 • n=335 Participants • Full analysis set, except 2 participants who did not have a valid baseline measure.	6.8814 mm² STANDARD_DEVIATION 5.6514 • n=336 Participants • Full analysis set, except 2 participants who did not have a valid baseline measure.	6.7097 mm² STANDARD_DEVIATION 5.3827 • n=1007 Participants • Full analysis set, except 2 participants who did not have a valid baseline measure.
Baseline central subfield retinal thickness (CST)	367.1 µm STANDARD_DEVIATION 133.6 • n=335 Participants • Full analysis set, except 3 participants who did not have a valid baseline measure.	370.3 µm STANDARD_DEVIATION 123.7 • n=335 Participants • Full analysis set, except 3 participants who did not have a valid baseline measure.	370.7 µm STANDARD_DEVIATION 132.7 • n=336 Participants • Full analysis set, except 3 participants who did not have a valid baseline measure.	369.3 µm STANDARD_DEVIATION 130.0 • n=1006 Participants • Full analysis set, except 3 participants who did not have a valid baseline measure.
Baseline NEI-VFQ-25 total score	77.8082 scores on a scale STANDARD_DEVIATION 14.4206 • n=317 Participants • Full analysis set, with the participants who completed the NEI-VFQ-25 at baseline.	76.3575 scores on a scale STANDARD_DEVIATION 15.1213 • n=321 Participants • Full analysis set, with the participants who completed the NEI-VFQ-25 at baseline.	77.6670 scores on a scale STANDARD_DEVIATION 15.3980 • n=316 Participants • Full analysis set, with the participants who completed the NEI-VFQ-25 at baseline.	77.2733 scores on a scale STANDARD_DEVIATION 14.9843 • n=954 Participants • Full analysis set, with the participants who completed the NEI-VFQ-25 at baseline.

PRIMARY outcome

Timeframe: At baseline and Week 48

Visual function of the study eye was assessed at a distance of 4 meters using the ETDRS BCVA letter score. BCVA scale range is 0 (worst) to 100 (best).

Outcome measures

Outcome measures
Measure	Aflibercept 2q8 n=336 Participants Participants received aflibercept 2 mg administered every 8 weeks after 3 initial injections at 4-week intervals, up to 96 weeks.	Aflibercept HDq12 n=335 Participants Participants received high dose (HD) aflibercept administered every 12 weeks after 3 initial injections at 4-week intervals, up to 96 weeks. Participants in this group can have their treatment intervals adjusted according to pre-specified dose regimen modification (DRM) criteria	Aflibercept HDq16 n=338 Participants Participants received high dose (HD) aflibercept administered every 16 weeks after 3 initial injections at 4-week intervals, up to 96 weeks. Participants in this group can have their treatment intervals adjusted according to pre-specified DRM criteria	All Aflibercept HD Included all participants from aflibercept HDq12 and aflibercept HDq16
Change From Baseline in BCVA Measured by the ETDRS Letter Score at Week 48	7.03 scores on a scale Standard Error 0.74	6.06 scores on a scale Standard Error 0.77	5.89 scores on a scale Standard Error 0.72	—

SECONDARY outcome

Timeframe: At baseline and Week 60

Visual function of the study eye was assessed at a distance of 4 meters using the ETDRS BCVA letter score. BCVA scale range is 0 (worst) to 100 (best).

Outcome measures

Outcome measures
Measure	Aflibercept 2q8 n=336 Participants Participants received aflibercept 2 mg administered every 8 weeks after 3 initial injections at 4-week intervals, up to 96 weeks.	Aflibercept HDq12 n=335 Participants Participants received high dose (HD) aflibercept administered every 12 weeks after 3 initial injections at 4-week intervals, up to 96 weeks. Participants in this group can have their treatment intervals adjusted according to pre-specified dose regimen modification (DRM) criteria	Aflibercept HDq16 n=338 Participants Participants received high dose (HD) aflibercept administered every 16 weeks after 3 initial injections at 4-week intervals, up to 96 weeks. Participants in this group can have their treatment intervals adjusted according to pre-specified DRM criteria	All Aflibercept HD Included all participants from aflibercept HDq12 and aflibercept HDq16
Change From Baseline in BCVA Measured by the ETDRS Letter Score at Week 60	7.23 scores on a scale Standard Error 0.68	6.37 scores on a scale Standard Error 0.74	6.31 scores on a scale Standard Error 0.66	—

SECONDARY outcome

Timeframe: At Week 16

Population: Full analysis set: included all participants who had been randomly assigned to study treatment and who received at least 1 dose of study treatment. Estimand mainly based on hypothetical strategy. The Overall Number of Participants Analyzed is not consistent with numbers provided in the Overall Number of Baseline Participants due to missing assessment at the respective visit. These participants with missing assessments were not included in the analysis.

Outcome measures

Outcome measures
Measure	Aflibercept 2q8 n=335 Participants Participants received aflibercept 2 mg administered every 8 weeks after 3 initial injections at 4-week intervals, up to 96 weeks.	Aflibercept HDq12 n=333 Participants Participants received high dose (HD) aflibercept administered every 12 weeks after 3 initial injections at 4-week intervals, up to 96 weeks. Participants in this group can have their treatment intervals adjusted according to pre-specified dose regimen modification (DRM) criteria	Aflibercept HDq16 n=334 Participants Participants received high dose (HD) aflibercept administered every 16 weeks after 3 initial injections at 4-week intervals, up to 96 weeks. Participants in this group can have their treatment intervals adjusted according to pre-specified DRM criteria	All Aflibercept HD n=667 Participants Included all participants from aflibercept HDq12 and aflibercept HDq16
Percentage of Participants With no Intraretinal Fluid (IRF) and no Subretinal Fluid (SRF) in Central Subfield at Week 16	51.6 Percentage of participants	61.6 Percentage of participants	65.0 Percentage of participants	63.3 Percentage of participants

SECONDARY outcome

Timeframe: At baseline and Week 48

Population: Full analysis set: included all participants who had been randomly assigned to study treatment and who received at least 1 dose of study treatment. The Overall Number of Participants Analyzed is not consistent with numbers provided in the Overall Number of Baseline Participants due to 1 participant per each treatment group with no post-baseline BCVA. These participants with missing assessments were not included in the analysis.

Outcome measures

Outcome measures
Measure	Aflibercept 2q8 n=335 Participants Participants received aflibercept 2 mg administered every 8 weeks after 3 initial injections at 4-week intervals, up to 96 weeks.	Aflibercept HDq12 n=334 Participants Participants received high dose (HD) aflibercept administered every 12 weeks after 3 initial injections at 4-week intervals, up to 96 weeks. Participants in this group can have their treatment intervals adjusted according to pre-specified dose regimen modification (DRM) criteria	Aflibercept HDq16 n=337 Participants Participants received high dose (HD) aflibercept administered every 16 weeks after 3 initial injections at 4-week intervals, up to 96 weeks. Participants in this group can have their treatment intervals adjusted according to pre-specified DRM criteria	All Aflibercept HD Included all participants from aflibercept HDq12 and aflibercept HDq16
Percentage of Participants Gaining at Least 15 Letters in BCVA From Baseline at Week 48	22.1 Percentage of participants	20.7 Percentage of participants	21.7 Percentage of participants	—

SECONDARY outcome

Timeframe: At Week 48

Outcome measures

Outcome measures
Measure	Aflibercept 2q8 n=335 Participants Participants received aflibercept 2 mg administered every 8 weeks after 3 initial injections at 4-week intervals, up to 96 weeks.	Aflibercept HDq12 n=334 Participants Participants received high dose (HD) aflibercept administered every 12 weeks after 3 initial injections at 4-week intervals, up to 96 weeks. Participants in this group can have their treatment intervals adjusted according to pre-specified dose regimen modification (DRM) criteria	Aflibercept HDq16 n=337 Participants Participants received high dose (HD) aflibercept administered every 16 weeks after 3 initial injections at 4-week intervals, up to 96 weeks. Participants in this group can have their treatment intervals adjusted according to pre-specified DRM criteria	All Aflibercept HD Included all participants from aflibercept HDq12 and aflibercept HDq16
Percentage of Participants Achieving an ETDRS Letter Score of at Least 69 (Approximate 20/40 Snellen Equivalent) at Week 48	57.9 Percentage of participants	56.9 Percentage of participants	54.3 Percentage of participants	—

SECONDARY outcome

Timeframe: At baseline and Week 48

Population: Full analysis set: included all participants who had been randomly assigned to study treatment and who received at least 1 dose of study treatment.

Outcome measures

Outcome measures
Measure	Aflibercept 2q8 n=336 Participants Participants received aflibercept 2 mg administered every 8 weeks after 3 initial injections at 4-week intervals, up to 96 weeks.	Aflibercept HDq12 n=335 Participants Participants received high dose (HD) aflibercept administered every 12 weeks after 3 initial injections at 4-week intervals, up to 96 weeks. Participants in this group can have their treatment intervals adjusted according to pre-specified dose regimen modification (DRM) criteria	Aflibercept HDq16 n=338 Participants Participants received high dose (HD) aflibercept administered every 16 weeks after 3 initial injections at 4-week intervals, up to 96 weeks. Participants in this group can have their treatment intervals adjusted according to pre-specified DRM criteria	All Aflibercept HD Included all participants from aflibercept HDq12 and aflibercept HDq16
Change in Choroidal Neovascularization (CNV) Size From Baseline to Week 48	-2.43 mm^2 Standard Error 0.31	-3.65 mm^2 Standard Error 0.28	-2.91 mm^2 Standard Error 0.29	—

SECONDARY outcome

Timeframe: At baseline and Week 48

Population: Full analysis set: included all participants who had been randomly assigned to study treatment and who received at least 1 dose of study treatment.

Outcome measures

Outcome measures
Measure	Aflibercept 2q8 n=336 Participants Participants received aflibercept 2 mg administered every 8 weeks after 3 initial injections at 4-week intervals, up to 96 weeks.	Aflibercept HDq12 n=335 Participants Participants received high dose (HD) aflibercept administered every 12 weeks after 3 initial injections at 4-week intervals, up to 96 weeks. Participants in this group can have their treatment intervals adjusted according to pre-specified dose regimen modification (DRM) criteria	Aflibercept HDq16 n=338 Participants Participants received high dose (HD) aflibercept administered every 16 weeks after 3 initial injections at 4-week intervals, up to 96 weeks. Participants in this group can have their treatment intervals adjusted according to pre-specified DRM criteria	All Aflibercept HD Included all participants from aflibercept HDq12 and aflibercept HDq16
Change in Total Lesion Area From Baseline to Week 48	0.09 mm^2 Standard Error 0.22	-0.46 mm^2 Standard Error 0.19	-0.35 mm^2 Standard Error 0.20	—

SECONDARY outcome

Timeframe: At Week 48

Population: Full analysis set: included all participants who had been randomly assigned to study treatment and who received at least 1 dose of study treatment. The Overall Number of Participants Analyzed is not consistent with numbers provided in the Overall Number of Baseline Participants due to missing assessments at the respective visit. These participants with missing assessments were not included in the analysis.

Outcome measures

Outcome measures
Measure	Aflibercept 2q8 n=335 Participants Participants received aflibercept 2 mg administered every 8 weeks after 3 initial injections at 4-week intervals, up to 96 weeks.	Aflibercept HDq12 n=332 Participants Participants received high dose (HD) aflibercept administered every 12 weeks after 3 initial injections at 4-week intervals, up to 96 weeks. Participants in this group can have their treatment intervals adjusted according to pre-specified dose regimen modification (DRM) criteria	Aflibercept HDq16 n=334 Participants Participants received high dose (HD) aflibercept administered every 16 weeks after 3 initial injections at 4-week intervals, up to 96 weeks. Participants in this group can have their treatment intervals adjusted according to pre-specified DRM criteria	All Aflibercept HD Included all participants from aflibercept HDq12 and aflibercept HDq16
Percentage of Participants With no Intraretinal Fluid (IRF) and no Subretinal Fluid (SRF) in the Center Subfield at Week 48	59.4 Percentage of participants	71.1 Percentage of participants	66.8 Percentage of participants	—

SECONDARY outcome

Timeframe: At baseline and Week 48

Population: Full analysis set: included all participants who had been randomly assigned to study treatment and who received at least 1 dose of study treatment.

Outcome measures

Outcome measures
Measure	Aflibercept 2q8 n=336 Participants Participants received aflibercept 2 mg administered every 8 weeks after 3 initial injections at 4-week intervals, up to 96 weeks.	Aflibercept HDq12 n=335 Participants Participants received high dose (HD) aflibercept administered every 12 weeks after 3 initial injections at 4-week intervals, up to 96 weeks. Participants in this group can have their treatment intervals adjusted according to pre-specified dose regimen modification (DRM) criteria	Aflibercept HDq16 n=338 Participants Participants received high dose (HD) aflibercept administered every 16 weeks after 3 initial injections at 4-week intervals, up to 96 weeks. Participants in this group can have their treatment intervals adjusted according to pre-specified DRM criteria	All Aflibercept HD Included all participants from aflibercept HDq12 and aflibercept HDq16
Change From Baseline in Central Subfield Retinal Thickness (CST) at Week 48	-136.25 µm Standard Error 4.24	-147.37 µm Standard Error 4.01	-146.76 µm Standard Error 3.76	—

SECONDARY outcome

Timeframe: At baseline and Week 48

Population: Full analysis set: included all participants who had been randomly assigned to study treatment and who received at least 1 dose of study treatment.

NEI VFQ-25 was a 25-item questionnaire that gave a score on a scale from 0 (worst) to 100 (best = no vision problems)

Outcome measures

Outcome measures
Measure	Aflibercept 2q8 n=336 Participants Participants received aflibercept 2 mg administered every 8 weeks after 3 initial injections at 4-week intervals, up to 96 weeks.	Aflibercept HDq12 n=335 Participants Participants received high dose (HD) aflibercept administered every 12 weeks after 3 initial injections at 4-week intervals, up to 96 weeks. Participants in this group can have their treatment intervals adjusted according to pre-specified dose regimen modification (DRM) criteria	Aflibercept HDq16 n=338 Participants Participants received high dose (HD) aflibercept administered every 16 weeks after 3 initial injections at 4-week intervals, up to 96 weeks. Participants in this group can have their treatment intervals adjusted according to pre-specified DRM criteria	All Aflibercept HD Included all participants from aflibercept HDq12 and aflibercept HDq16
Change From Baseline in National Eye Institute Visual Functioning Questionnaire-25 (NEI-VFQ-25) Total Score at Week 48	4.22 scores on a scale Standard Error 0.70	3.50 scores on a scale Standard Error 0.70	3.35 scores on a scale Standard Error 0.72	—

SECONDARY outcome

Timeframe: Up to Week 48

Population: Pharmacokinetic analysis set: included all participants who received any study treatment and who had at least 1 non-missing drug concentration measurement following the first dose of study treatment

Outcome measures

Outcome measures
Measure	Aflibercept 2q8 n=308 Participants Participants received aflibercept 2 mg administered every 8 weeks after 3 initial injections at 4-week intervals, up to 96 weeks.	Aflibercept HDq12 n=313 Participants Participants received high dose (HD) aflibercept administered every 12 weeks after 3 initial injections at 4-week intervals, up to 96 weeks. Participants in this group can have their treatment intervals adjusted according to pre-specified dose regimen modification (DRM) criteria	Aflibercept HDq16 n=313 Participants Participants received high dose (HD) aflibercept administered every 16 weeks after 3 initial injections at 4-week intervals, up to 96 weeks. Participants in this group can have their treatment intervals adjusted according to pre-specified DRM criteria	All Aflibercept HD Included all participants from aflibercept HDq12 and aflibercept HDq16
Systemic Exposure to Aflibercept as Assessed by Plasma Concentrations of Free, Adjusted Bound and Total Aflibercept From Baseline Through Week 48 Week 4	NA mg/L Geometric Coefficient of Variation NA Not calculated (less than 2/3 of values per timepoint are \>= Lower level of quantification (LLOQ) for geometric mean calculation).	NA mg/L Geometric Coefficient of Variation NA Not calculated (less than 2/3 of values per timepoint are \>= Lower level of quantification (LLOQ) for geometric mean calculation).	NA mg/L Geometric Coefficient of Variation NA Not calculated (less than 2/3 of values per timepoint are \>= Lower level of quantification (LLOQ) for geometric mean calculation).	—
Systemic Exposure to Aflibercept as Assessed by Plasma Concentrations of Free, Adjusted Bound and Total Aflibercept From Baseline Through Week 48 Visit 5: within 3 to 7 days after the Week 8	0.03 mg/L Geometric Coefficient of Variation 70.29	0.14 mg/L Geometric Coefficient of Variation 78.69	0.13 mg/L Geometric Coefficient of Variation 82.50	—
Systemic Exposure to Aflibercept as Assessed by Plasma Concentrations of Free, Adjusted Bound and Total Aflibercept From Baseline Through Week 48 Week 12	NA mg/L Geometric Coefficient of Variation NA Not calculated (less than 2/3 of values per timepoint are \>= Lower level of quantification (LLOQ) for geometric mean calculation).	0.02 mg/L Geometric Coefficient of Variation 81.35	0.02 mg/L Geometric Coefficient of Variation 84.06	—
Systemic Exposure to Aflibercept as Assessed by Plasma Concentrations of Free, Adjusted Bound and Total Aflibercept From Baseline Through Week 48 Week 28	NA mg/L Geometric Coefficient of Variation NA Not calculated (less than 2/3 of values per timepoint are \>= Lower level of quantification (LLOQ) for geometric mean calculation).	NA mg/L Geometric Coefficient of Variation NA Not calculated (less than 2/3 of values per timepoint are \>= Lower level of quantification (LLOQ) for geometric mean calculation).	NA mg/L Geometric Coefficient of Variation NA Not calculated (less than 2/3 of values per timepoint are \>= Lower level of quantification (LLOQ) for geometric mean calculation).	—
Systemic Exposure to Aflibercept as Assessed by Plasma Concentrations of Free, Adjusted Bound and Total Aflibercept From Baseline Through Week 48 Week 48	NA mg/L Geometric Coefficient of Variation NA Not calculated (less than 2/3 of values per timepoint are \>= Lower level of quantification (LLOQ) for geometric mean calculation).	NA mg/L Geometric Coefficient of Variation NA Not calculated (less than 2/3 of values per timepoint are \>= Lower level of quantification (LLOQ) for geometric mean calculation).	NA mg/L Geometric Coefficient of Variation NA Not calculated (less than 2/3 of values per timepoint are \>= Lower level of quantification (LLOQ) for geometric mean calculation).	—

SECONDARY outcome

Timeframe: Up to week 96

Outcome measures

Outcome measures
Measure	Aflibercept 2q8 n=284 Participants Participants received aflibercept 2 mg administered every 8 weeks after 3 initial injections at 4-week intervals, up to 96 weeks.	Aflibercept HDq12 n=295 Participants Participants received high dose (HD) aflibercept administered every 12 weeks after 3 initial injections at 4-week intervals, up to 96 weeks. Participants in this group can have their treatment intervals adjusted according to pre-specified dose regimen modification (DRM) criteria	Aflibercept HDq16 n=295 Participants Participants received high dose (HD) aflibercept administered every 16 weeks after 3 initial injections at 4-week intervals, up to 96 weeks. Participants in this group can have their treatment intervals adjusted according to pre-specified DRM criteria	All Aflibercept HD n=590 Participants Included all participants from aflibercept HDq12 and aflibercept HDq16
Incidence of Treatment-emergent Anti-drug Antibodies (ADA) Response Treatment-emergent positive or Treatment-boosted, maximum ADA titers - Low (< 1000)	8 Participants	14 Participants	13 Participants	27 Participants
Incidence of Treatment-emergent Anti-drug Antibodies (ADA) Response Treatment-emergent positive or Treatment-boosted, maximum ADA titers - Moderate (1000-10000)	0 Participants	0 Participants	0 Participants	0 Participants
Incidence of Treatment-emergent Anti-drug Antibodies (ADA) Response Treatment-emergent positive or Treatment-boosted, maximum ADA titers - High (> 10000)	0 Participants	0 Participants	0 Participants	0 Participants

Adverse Events

Aflibercept 2q8 (Week 0- 96)

Serious events: 69 serious events

Other events: 179 other events

Deaths: 12 deaths

Aflibercept HDq12 (Week 0- 96)

Serious events: 83 serious events

Other events: 163 other events

Deaths: 11 deaths

Aflibercept HDq16 (Week 0- 96)

Serious events: 72 serious events

Other events: 180 other events

Deaths: 7 deaths

All Aflibercept HD (Week 0- 96)

Serious events: 155 serious events

Other events: 343 other events

Deaths: 18 deaths

Aflibercept 2q8/HD (Week 0- 156)

Serious events: 49 serious events

Other events: 136 other events

Deaths: 4 deaths

Aflibercept HDq12 (Week 0- 156)

Serious events: 61 serious events

Other events: 120 other events

Deaths: 7 deaths

Aflibercept HDq16 (Week 0- 156)

Serious events: 61 serious events

Other events: 135 other events

Deaths: 2 deaths

All Aflibercept HD (Week 0- 156)

Serious events: 122 serious events

Other events: 255 other events

Deaths: 9 deaths

Serious adverse events

Serious adverse events
Measure	Aflibercept 2q8 (Week 0- 96) n=336 participants at risk Participants enrolled in main study received aflibercept 2 mg administered every 8 weeks after 3 initial injections at 4-week intervals.	Aflibercept HDq12 (Week 0- 96) n=335 participants at risk Participants enrolled in main study received high dose (HD) aflibercept administered every 12 weeks after 3 initial injections at 4-week intervals. Participants in this group could have their treatment intervals adjusted according to pre-specified dose regimen modification (DRM) criteria.	Aflibercept HDq16 (Week 0- 96) n=338 participants at risk Participants enrolled in main study received high dose (HD) aflibercept administered every 16 weeks after 3 initial injections at 4-week intervals. Participants in this group could have their treatment intervals adjusted according to pre-specified dose regimen modification (DRM) criteria.	All Aflibercept HD (Week 0- 96) n=673 participants at risk All participants from aflibercept HDq12 (Week 0-96) and aflibercept HDq16 (Week 0-96).	Aflibercept 2q8/HD (Week 0- 156) n=208 participants at risk Participants enrolled in the extension originally assigned to 2q8 in main study and switched to high dose aflibercept every 12 weeks starting at Week 96. Participants in this group could have their treatment intervals adjusted in the extension according to pre-specified dose regimen modification (E-DRM) criteria.	Aflibercept HDq12 (Week 0- 156) n=210 participants at risk Participants enrolled in the extension originally assigned to HDq12 in main study and continued with HD aflibercept at their latest dosing interval at Week 96. Participants in this group could have their treatment intervals adjusted in the extension according to pre-specified dose regimen modification (E-DRM) criteria.	Aflibercept HDq16 (Week 0- 156) n=207 participants at risk Participants enrolled in the extension originally assigned to HDq16 in main study and continued with HD aflibercept at their latest dosing interval at Week 96. Participants in this group could have their treatment intervals adjusted in the extension according to pre-specified dose regimen modification (E-DRM) criteria.	All Aflibercept HD (Week 0- 156) n=417 participants at risk All participants from aflibercept HDq12 (Week 0-156) and aflibercept HDq16 (Week 0-156). Participants in this group could have their treatment intervals adjusted in the extension according to pre-specified dose regimen modification (E-DRM) criteria.
Blood and lymphatic system disorders Anaemia	0.30% 1/336 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.30% 1/335 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/338 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.15% 1/673 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/208 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.48% 1/210 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/207 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.24% 1/417 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
Blood and lymphatic system disorders Blood loss anaemia	0.30% 1/336 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/335 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/338 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/673 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.48% 1/208 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/210 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/207 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/417 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
Blood and lymphatic system disorders Febrile neutropenia	0.00% 0/336 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/335 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/338 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/673 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/208 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.48% 1/210 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/207 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.24% 1/417 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
Blood and lymphatic system disorders Hypochromic anaemia	0.00% 0/336 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.30% 1/335 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/338 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.15% 1/673 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/208 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.48% 1/210 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/207 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.24% 1/417 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
Cardiac disorders Acute coronary syndrome	0.30% 1/336 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/335 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/338 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/673 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/208 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/210 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/207 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/417 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
Cardiac disorders Acute left ventricular failure	0.30% 1/336 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/335 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.30% 1/338 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.15% 1/673 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.48% 1/208 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/210 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.48% 1/207 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.24% 1/417 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
Cardiac disorders Acute myocardial infarction	0.60% 2/336 • Number of events 2 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.30% 1/335 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/338 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.15% 1/673 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.48% 1/208 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.48% 1/210 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.48% 1/207 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.48% 2/417 • Number of events 2 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
Cardiac disorders Angina pectoris	0.30% 1/336 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/335 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	1.2% 4/338 • Number of events 4 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.59% 4/673 • Number of events 4 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.48% 1/208 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/210 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.48% 1/207 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.24% 1/417 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
Cardiac disorders Angina unstable	0.00% 0/336 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.60% 2/335 • Number of events 2 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.30% 1/338 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.45% 3/673 • Number of events 3 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/208 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.48% 1/210 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.48% 1/207 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.48% 2/417 • Number of events 2 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
Cardiac disorders Aortic valve stenosis	0.00% 0/336 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.30% 1/335 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/338 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.15% 1/673 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/208 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.48% 1/210 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.48% 1/207 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.48% 2/417 • Number of events 2 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
Cardiac disorders Arrhythmia	0.00% 0/336 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.30% 1/335 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/338 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.15% 1/673 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.48% 1/208 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.48% 1/210 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.48% 1/207 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.48% 2/417 • Number of events 2 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
Cardiac disorders Arteriosclerosis coronary artery	0.00% 0/336 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.30% 1/335 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/338 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.15% 1/673 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/208 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/210 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/207 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/417 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
Cardiac disorders Atrial fibrillation	0.30% 1/336 • Number of events 3 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.60% 2/335 • Number of events 2 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/338 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.30% 2/673 • Number of events 2 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.96% 2/208 • Number of events 4 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/210 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.48% 1/207 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.24% 1/417 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
Cardiac disorders Bradycardia	0.30% 1/336 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/335 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/338 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/673 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.48% 1/208 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.48% 1/210 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/207 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.24% 1/417 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
Cardiac disorders Cardiac arrest	0.30% 1/336 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/335 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/338 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/673 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/208 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/210 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/207 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/417 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
Cardiac disorders Cardiac failure	0.30% 1/336 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.30% 1/335 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.30% 1/338 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.30% 2/673 • Number of events 2 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.48% 1/208 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/210 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/207 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/417 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
Cardiac disorders Cardiac failure chronic	0.00% 0/336 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.30% 1/335 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/338 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.15% 1/673 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/208 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/210 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/207 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/417 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
Cardiac disorders Cardiac failure congestive	0.00% 0/336 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.90% 3/335 • Number of events 3 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/338 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.45% 3/673 • Number of events 3 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.48% 1/208 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.48% 1/210 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/207 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.24% 1/417 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
Cardiac disorders Coronary artery disease	0.00% 0/336 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.60% 2/335 • Number of events 2 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.30% 1/338 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.45% 3/673 • Number of events 3 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.48% 1/208 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.48% 1/210 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	1.4% 3/207 • Number of events 3 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.96% 4/417 • Number of events 4 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
Cardiac disorders Coronary artery stenosis	0.00% 0/336 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.60% 2/335 • Number of events 2 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/338 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.30% 2/673 • Number of events 2 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/208 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.48% 1/210 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/207 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.24% 1/417 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
Cardiac disorders Hypertensive heart disease	0.00% 0/336 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/335 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/338 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/673 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/208 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/210 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.48% 1/207 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.24% 1/417 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
Cardiac disorders Myocardial infarction	0.30% 1/336 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.30% 1/335 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.89% 3/338 • Number of events 3 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.59% 4/673 • Number of events 4 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.48% 1/208 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/210 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.97% 2/207 • Number of events 2 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.48% 2/417 • Number of events 2 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
Cardiac disorders Myocardial ischaemia	0.30% 1/336 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/335 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.30% 1/338 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.15% 1/673 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.48% 1/208 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.48% 1/210 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.48% 1/207 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.48% 2/417 • Number of events 2 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
Cardiac disorders Stress cardiomyopathy	0.00% 0/336 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/335 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/338 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/673 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.48% 1/208 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/210 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/207 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/417 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
Cardiac disorders Ventricular extrasystoles	0.00% 0/336 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/335 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/338 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/673 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/208 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/210 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.48% 1/207 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.24% 1/417 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
Ear and labyrinth disorders Tinnitus	0.00% 0/336 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/335 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.30% 1/338 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.15% 1/673 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/208 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/210 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.48% 1/207 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.24% 1/417 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
Ear and labyrinth disorders Vertigo	0.00% 0/336 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.30% 1/335 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/338 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.15% 1/673 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/208 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/210 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/207 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/417 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
Endocrine disorders Goitre	0.00% 0/336 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/335 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.30% 1/338 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.15% 1/673 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/208 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/210 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/207 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/417 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
Eye disorders Angle closure glaucoma	0.30% 1/336 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/335 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.30% 1/338 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.15% 1/673 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.48% 1/208 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/210 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/207 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/417 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
Eye disorders Cataract	0.00% 0/336 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.60% 2/335 • Number of events 2 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.59% 2/338 • Number of events 2 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.59% 4/673 • Number of events 4 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.96% 2/208 • Number of events 2 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	1.4% 3/210 • Number of events 3 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	2.4% 5/207 • Number of events 5 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	1.9% 8/417 • Number of events 8 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
Eye disorders Dry age-related macular degeneration	0.00% 0/336 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.30% 1/335 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/338 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.15% 1/673 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/208 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.48% 1/210 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/207 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.24% 1/417 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
Eye disorders Macular detachment	0.00% 0/336 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.30% 1/335 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/338 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.15% 1/673 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/208 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/210 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/207 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/417 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
Eye disorders Retinal detachment	0.30% 1/336 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.60% 2/335 • Number of events 2 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.89% 3/338 • Number of events 3 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.74% 5/673 • Number of events 5 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.48% 1/208 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.95% 2/210 • Number of events 2 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.97% 2/207 • Number of events 2 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.96% 4/417 • Number of events 4 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
Eye disorders Retinal haemorrhage	0.30% 1/336 • Number of events 6 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.60% 2/335 • Number of events 2 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.59% 2/338 • Number of events 2 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.59% 4/673 • Number of events 4 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.48% 1/208 • Number of events 6 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.48% 1/210 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.97% 2/207 • Number of events 2 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.72% 3/417 • Number of events 3 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
Eye disorders Retinal tear	0.00% 0/336 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/335 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.30% 1/338 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.15% 1/673 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/208 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/210 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.48% 1/207 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.24% 1/417 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
Eye disorders Vitreous haemorrhage	0.00% 0/336 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/335 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.30% 1/338 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.15% 1/673 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/208 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/210 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.48% 1/207 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.24% 1/417 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
Gastrointestinal disorders Abdominal pain	0.30% 1/336 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/335 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/338 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/673 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/208 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/210 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/207 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/417 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
Gastrointestinal disorders Abdominal pain upper	0.00% 0/336 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/335 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.30% 1/338 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.15% 1/673 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/208 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/210 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.48% 1/207 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.24% 1/417 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
Gastrointestinal disorders Abdominal strangulated hernia	0.30% 1/336 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/335 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/338 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/673 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/208 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/210 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/207 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/417 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
Gastrointestinal disorders Colitis	0.00% 0/336 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.30% 1/335 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/338 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.15% 1/673 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/208 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.48% 1/210 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.48% 1/207 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.48% 2/417 • Number of events 2 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
Gastrointestinal disorders Colitis ischaemic	0.30% 1/336 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/335 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/338 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/673 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/208 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/210 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/207 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/417 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
Gastrointestinal disorders Dental caries	0.00% 0/336 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/335 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/338 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/673 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.48% 1/208 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/210 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/207 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/417 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
Gastrointestinal disorders Diarrhoea	0.00% 0/336 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.60% 2/335 • Number of events 2 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/338 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.30% 2/673 • Number of events 2 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/208 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.48% 1/210 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/207 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.24% 1/417 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
Gastrointestinal disorders Dysphagia	0.00% 0/336 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/335 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.30% 1/338 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.15% 1/673 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/208 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/210 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/207 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/417 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
Gastrointestinal disorders Enteritis	0.30% 1/336 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.30% 1/335 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/338 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.15% 1/673 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/208 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.48% 1/210 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/207 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.24% 1/417 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
Gastrointestinal disorders Gastric ulcer	0.00% 0/336 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/335 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/338 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/673 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/208 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.48% 1/210 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/207 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.24% 1/417 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
Gastrointestinal disorders Gingival bleeding	0.00% 0/336 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/335 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/338 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/673 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.48% 1/208 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/210 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/207 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/417 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
Gastrointestinal disorders Haemoperitoneum	0.00% 0/336 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/335 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/338 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/673 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.48% 1/208 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/210 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/207 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/417 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
Gastrointestinal disorders Haemorrhoids	0.00% 0/336 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/335 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/338 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/673 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/208 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.48% 1/210 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/207 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.24% 1/417 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
Gastrointestinal disorders Intestinal obstruction	0.00% 0/336 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.60% 2/335 • Number of events 2 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/338 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.30% 2/673 • Number of events 2 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/208 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.48% 1/210 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/207 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.24% 1/417 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
Gastrointestinal disorders Large intestine polyp	0.30% 1/336 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.30% 1/335 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.30% 1/338 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.30% 2/673 • Number of events 2 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/208 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.48% 1/210 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/207 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.24% 1/417 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
Gastrointestinal disorders Mechanical ileus	0.00% 0/336 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.30% 1/335 • Number of events 2 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/338 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.15% 1/673 • Number of events 2 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/208 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.48% 1/210 • Number of events 2 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/207 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.24% 1/417 • Number of events 2 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
Gastrointestinal disorders Mesenteric artery thrombosis	0.00% 0/336 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.30% 1/335 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/338 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.15% 1/673 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/208 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.48% 1/210 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/207 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.24% 1/417 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
Gastrointestinal disorders Nausea	0.00% 0/336 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/335 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.30% 1/338 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.15% 1/673 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/208 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/210 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.48% 1/207 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.24% 1/417 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
Gastrointestinal disorders Oesophageal stenosis	0.00% 0/336 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.30% 1/335 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/338 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.15% 1/673 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/208 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.48% 1/210 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/207 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.24% 1/417 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
Gastrointestinal disorders Oesophagitis	0.30% 1/336 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/335 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/338 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/673 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/208 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/210 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/207 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/417 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
Gastrointestinal disorders Pancreatitis	0.00% 0/336 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.30% 1/335 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/338 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.15% 1/673 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/208 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.48% 1/210 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/207 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.24% 1/417 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
Gastrointestinal disorders Pancreatitis chronic	0.00% 0/336 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/335 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.30% 1/338 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.15% 1/673 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/208 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/210 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.48% 1/207 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.24% 1/417 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
Gastrointestinal disorders Small intestinal obstruction	0.00% 0/336 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/335 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/338 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/673 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/208 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/210 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.48% 1/207 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.24% 1/417 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
Gastrointestinal disorders Small intestinal perforation	0.00% 0/336 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/335 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.30% 1/338 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.15% 1/673 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/208 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/210 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/207 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/417 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
Gastrointestinal disorders Umbilical hernia	0.00% 0/336 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/335 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.30% 1/338 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.15% 1/673 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/208 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/210 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.48% 1/207 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.24% 1/417 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
Gastrointestinal disorders Upper gastrointestinal haemorrhage	0.30% 1/336 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/335 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/338 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/673 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.48% 1/208 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/210 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/207 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/417 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
General disorders Asthenia	0.00% 0/336 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/335 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.30% 1/338 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.15% 1/673 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/208 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/210 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.48% 1/207 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.24% 1/417 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
General disorders Chest pain	0.00% 0/336 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.60% 2/335 • Number of events 2 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.30% 1/338 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.45% 3/673 • Number of events 3 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/208 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/210 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/207 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/417 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
General disorders Cyst	0.00% 0/336 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/335 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.30% 1/338 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.15% 1/673 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/208 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/210 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.48% 1/207 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.24% 1/417 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
General disorders Death	0.00% 0/336 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.30% 1/335 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.59% 2/338 • Number of events 2 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.45% 3/673 • Number of events 3 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/208 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/210 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/207 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/417 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
General disorders Oedema	0.00% 0/336 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.30% 1/335 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/338 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.15% 1/673 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/208 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.48% 1/210 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/207 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.24% 1/417 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
General disorders Oedema peripheral	0.00% 0/336 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/335 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/338 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/673 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/208 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.48% 1/210 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/207 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.24% 1/417 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
General disorders Pain	0.00% 0/336 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.30% 1/335 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/338 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.15% 1/673 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/208 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/210 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/207 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/417 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
General disorders Peripheral swelling	0.30% 1/336 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/335 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.30% 1/338 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.15% 1/673 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/208 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/210 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.48% 1/207 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.24% 1/417 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
Hepatobiliary disorders Bile duct stone	0.30% 1/336 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/335 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/338 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/673 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.48% 1/208 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/210 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/207 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/417 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
Hepatobiliary disorders Cholangitis	0.00% 0/336 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.30% 1/335 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/338 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.15% 1/673 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/208 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/210 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/207 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/417 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
Hepatobiliary disorders Cholecystitis	0.60% 2/336 • Number of events 2 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/335 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/338 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/673 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.48% 1/208 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/210 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/207 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/417 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
Hepatobiliary disorders Cholelithiasis	0.00% 0/336 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.30% 1/335 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.30% 1/338 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.30% 2/673 • Number of events 2 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/208 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.48% 1/210 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.48% 1/207 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.48% 2/417 • Number of events 2 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
Hepatobiliary disorders Haemorrhagic cholecystitis	0.00% 0/336 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/335 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/338 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/673 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.48% 1/208 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/210 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/207 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/417 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
Hepatobiliary disorders Haemorrhagic hepatic cyst	0.00% 0/336 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/335 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/338 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/673 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/208 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.48% 1/210 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/207 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.24% 1/417 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
Hepatobiliary disorders Hepatic vascular thrombosis	0.00% 0/336 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/335 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.30% 1/338 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.15% 1/673 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/208 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/210 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/207 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/417 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
Immune system disorders Sarcoidosis	0.00% 0/336 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/335 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/338 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/673 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/208 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.48% 1/210 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/207 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.24% 1/417 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
Infections and infestations Appendicitis	0.00% 0/336 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/335 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.59% 2/338 • Number of events 2 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.30% 2/673 • Number of events 2 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/208 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/210 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.48% 1/207 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.24% 1/417 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
Infections and infestations Bronchitis	0.00% 0/336 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/335 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.30% 1/338 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.15% 1/673 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/208 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/210 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/207 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/417 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
Infections and infestations COVID-19	0.00% 0/336 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/335 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.59% 2/338 • Number of events 2 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.30% 2/673 • Number of events 2 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.48% 1/208 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/210 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	1.4% 3/207 • Number of events 3 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.72% 3/417 • Number of events 3 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
Infections and infestations COVID-19 pneumonia	0.00% 0/336 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.30% 1/335 • Number of events 2 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/338 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.15% 1/673 • Number of events 2 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/208 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/210 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/207 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/417 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
Infections and infestations Cellulitis	0.00% 0/336 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.60% 2/335 • Number of events 2 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/338 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.30% 2/673 • Number of events 2 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/208 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.95% 2/210 • Number of events 2 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/207 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.48% 2/417 • Number of events 2 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
Infections and infestations Diverticulitis	0.00% 0/336 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.30% 1/335 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/338 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.15% 1/673 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/208 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/210 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/207 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/417 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
Infections and infestations Endophthalmitis	0.30% 1/336 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/335 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/338 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/673 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.48% 1/208 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/210 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/207 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/417 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
Infections and infestations Erysipelas	0.00% 0/336 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.30% 1/335 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/338 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.15% 1/673 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/208 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/210 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/207 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/417 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
Infections and infestations Gangrene	0.00% 0/336 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/335 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.30% 1/338 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.15% 1/673 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/208 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/210 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/207 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/417 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
Infections and infestations Herpes zoster	0.00% 0/336 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.30% 1/335 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/338 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.15% 1/673 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/208 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.48% 1/210 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/207 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.24% 1/417 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
Infections and infestations Infective exacerbation of chronic obstructive airways disease	0.00% 0/336 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/335 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.30% 1/338 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.15% 1/673 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/208 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/210 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.48% 1/207 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.24% 1/417 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
Infections and infestations Liver abscess	0.00% 0/336 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/335 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.30% 1/338 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.15% 1/673 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/208 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/210 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/207 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/417 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
Infections and infestations Otitis externa	0.00% 0/336 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.30% 1/335 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/338 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.15% 1/673 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/208 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.48% 1/210 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/207 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.24% 1/417 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
Infections and infestations Pneumonia	0.60% 2/336 • Number of events 2 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	1.5% 5/335 • Number of events 5 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	1.5% 5/338 • Number of events 5 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	1.5% 10/673 • Number of events 10 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.96% 2/208 • Number of events 2 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	1.4% 3/210 • Number of events 3 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	1.4% 3/207 • Number of events 3 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	1.4% 6/417 • Number of events 6 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
Infections and infestations Pneumonia aspiration	0.30% 1/336 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/335 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/338 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/673 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/208 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/210 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/207 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/417 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
Infections and infestations Pneumonia mycoplasmal	0.00% 0/336 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/335 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/338 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/673 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.48% 1/208 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/210 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/207 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/417 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
Infections and infestations Pneumonia viral	0.00% 0/336 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/335 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.30% 1/338 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.15% 1/673 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/208 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/210 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.48% 1/207 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.24% 1/417 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
Infections and infestations Pyelonephritis	0.00% 0/336 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/335 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.30% 1/338 • Number of events 2 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.15% 1/673 • Number of events 2 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/208 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/210 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/207 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/417 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
Infections and infestations Pyelonephritis acute	0.00% 0/336 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/335 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.59% 2/338 • Number of events 3 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.30% 2/673 • Number of events 3 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/208 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/210 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/207 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/417 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
Infections and infestations Q fever	0.00% 0/336 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/335 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.30% 1/338 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.15% 1/673 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/208 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/210 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/207 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/417 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
Infections and infestations Sepsis	0.00% 0/336 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/335 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.30% 1/338 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.15% 1/673 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/208 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/210 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/207 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/417 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
Infections and infestations Sinusitis	0.30% 1/336 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/335 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/338 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/673 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.48% 1/208 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/210 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/207 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/417 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
Infections and infestations Staphylococcal sepsis	0.00% 0/336 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/335 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.30% 1/338 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.15% 1/673 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/208 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.48% 1/210 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.48% 1/207 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.48% 2/417 • Number of events 2 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
Infections and infestations Systemic infection	0.00% 0/336 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/335 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.30% 1/338 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.15% 1/673 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/208 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/210 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.48% 1/207 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.24% 1/417 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
Infections and infestations Urinary tract infection	1.5% 5/336 • Number of events 5 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.30% 1/335 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.59% 2/338 • Number of events 2 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.45% 3/673 • Number of events 3 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	1.9% 4/208 • Number of events 5 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.48% 1/210 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.48% 1/207 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.48% 2/417 • Number of events 2 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
Infections and infestations Urosepsis	0.30% 1/336 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/335 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/338 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/673 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.48% 1/208 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/210 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.48% 1/207 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.24% 1/417 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
Injury, poisoning and procedural complications Alcohol poisoning	0.00% 0/336 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/335 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/338 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/673 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.48% 1/208 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/210 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/207 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/417 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
Injury, poisoning and procedural complications Ankle fracture	0.00% 0/336 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/335 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/338 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/673 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/208 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.48% 1/210 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/207 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.24% 1/417 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
Injury, poisoning and procedural complications Corneal abrasion	0.00% 0/336 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/335 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/338 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/673 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.48% 1/208 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/210 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/207 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/417 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
Injury, poisoning and procedural complications Craniofacial fracture	0.00% 0/336 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/335 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/338 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/673 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.48% 1/208 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/210 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/207 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/417 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
Injury, poisoning and procedural complications Fall	0.30% 1/336 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/335 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/338 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/673 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/208 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.48% 1/210 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/207 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.24% 1/417 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
Injury, poisoning and procedural complications Femoral neck fracture	0.30% 1/336 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/335 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/338 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/673 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/208 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/210 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/207 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/417 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
Injury, poisoning and procedural complications Femur fracture	0.30% 1/336 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/335 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/338 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/673 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/208 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/210 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/207 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/417 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
Injury, poisoning and procedural complications Hip fracture	0.30% 1/336 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/335 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.30% 1/338 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.15% 1/673 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.48% 1/208 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/210 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/207 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/417 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
Injury, poisoning and procedural complications Ligament sprain	0.00% 0/336 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.30% 1/335 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/338 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.15% 1/673 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/208 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/210 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/207 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/417 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
Injury, poisoning and procedural complications Lower limb fracture	0.00% 0/336 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/335 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/338 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/673 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/208 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.48% 1/210 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/207 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.24% 1/417 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
Injury, poisoning and procedural complications Multiple injuries	0.00% 0/336 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/335 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/338 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/673 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.48% 1/208 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/210 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/207 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/417 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
Injury, poisoning and procedural complications Patella fracture	0.30% 1/336 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/335 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/338 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/673 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/208 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/210 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/207 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/417 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
Injury, poisoning and procedural complications Pelvic fracture	0.60% 2/336 • Number of events 2 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/335 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/338 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/673 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.48% 1/208 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/210 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/207 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/417 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
Injury, poisoning and procedural complications Periprosthetic fracture	0.00% 0/336 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/335 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/338 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/673 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/208 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/210 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.48% 1/207 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.24% 1/417 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
Injury, poisoning and procedural complications Post procedural haemorrhage	0.30% 1/336 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/335 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/338 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/673 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/208 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/210 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/207 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/417 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
Injury, poisoning and procedural complications Postoperative ileus	0.00% 0/336 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/335 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/338 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/673 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.48% 1/208 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/210 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/207 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/417 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
Injury, poisoning and procedural complications Postoperative wound complication	0.00% 0/336 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.30% 1/335 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/338 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.15% 1/673 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/208 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/210 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/207 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/417 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
Injury, poisoning and procedural complications Rib fracture	0.60% 2/336 • Number of events 2 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/335 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/338 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/673 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/208 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/210 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/207 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/417 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
Injury, poisoning and procedural complications Shoulder fracture	0.30% 1/336 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/335 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/338 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/673 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.96% 2/208 • Number of events 2 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/210 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/207 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/417 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
Injury, poisoning and procedural complications Skin laceration	0.00% 0/336 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/335 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.30% 1/338 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.15% 1/673 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/208 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/210 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.48% 1/207 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.24% 1/417 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
Injury, poisoning and procedural complications Skull fracture	0.30% 1/336 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/335 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/338 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/673 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/208 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/210 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/207 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/417 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
Injury, poisoning and procedural complications Spinal compression fracture	0.30% 1/336 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/335 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.59% 2/338 • Number of events 2 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.30% 2/673 • Number of events 2 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/208 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/210 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.97% 2/207 • Number of events 2 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.48% 2/417 • Number of events 2 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
Injury, poisoning and procedural complications Subdural haematoma	0.00% 0/336 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/335 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/338 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/673 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/208 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/210 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.48% 1/207 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.24% 1/417 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
Injury, poisoning and procedural complications Thoracic vertebral fracture	0.30% 1/336 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/335 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/338 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/673 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.48% 1/208 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.48% 1/210 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/207 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.24% 1/417 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
Injury, poisoning and procedural complications Upper limb fracture	0.30% 1/336 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/335 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/338 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/673 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.48% 1/208 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/210 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.48% 1/207 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.24% 1/417 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
Injury, poisoning and procedural complications Wrist fracture	0.00% 0/336 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.30% 1/335 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/338 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.15% 1/673 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/208 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.48% 1/210 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/207 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.24% 1/417 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
Investigations Intraocular pressure increased	0.00% 0/336 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.60% 2/335 • Number of events 2 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/338 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.30% 2/673 • Number of events 2 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/208 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.95% 2/210 • Number of events 2 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.48% 1/207 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.72% 3/417 • Number of events 3 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
Metabolism and nutrition disorders Hyperglycaemia	0.30% 1/336 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.30% 1/335 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/338 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.15% 1/673 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.48% 1/208 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.48% 1/210 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/207 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.24% 1/417 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
Metabolism and nutrition disorders Hypokalaemia	0.30% 1/336 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/335 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/338 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/673 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/208 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/210 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/207 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/417 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
Metabolism and nutrition disorders Hyponatraemia	0.60% 2/336 • Number of events 2 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/335 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.59% 2/338 • Number of events 2 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.30% 2/673 • Number of events 2 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.96% 2/208 • Number of events 2 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/210 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.97% 2/207 • Number of events 2 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.48% 2/417 • Number of events 2 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
Metabolism and nutrition disorders Malnutrition	0.30% 1/336 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/335 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/338 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/673 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/208 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/210 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/207 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/417 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
Musculoskeletal and connective tissue disorders Arthralgia	0.30% 1/336 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/335 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/338 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/673 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.96% 2/208 • Number of events 2 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/210 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/207 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/417 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
Musculoskeletal and connective tissue disorders Back pain	0.30% 1/336 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.30% 1/335 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.30% 1/338 • Number of events 2 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.30% 2/673 • Number of events 3 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.48% 1/208 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.48% 1/210 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.97% 2/207 • Number of events 4 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.72% 3/417 • Number of events 5 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
Musculoskeletal and connective tissue disorders Exostosis	0.00% 0/336 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/335 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.30% 1/338 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.15% 1/673 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/208 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/210 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.48% 1/207 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.24% 1/417 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
Musculoskeletal and connective tissue disorders Intervertebral disc disorder	0.00% 0/336 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/335 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/338 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/673 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.48% 1/208 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/210 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/207 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/417 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
Musculoskeletal and connective tissue disorders Intervertebral disc protrusion	0.30% 1/336 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/335 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/338 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/673 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.48% 1/208 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/210 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/207 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/417 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
Musculoskeletal and connective tissue disorders Lumbar spinal stenosis	0.00% 0/336 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.30% 1/335 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/338 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.15% 1/673 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/208 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/210 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/207 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/417 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
Musculoskeletal and connective tissue disorders Mobility decreased	0.30% 1/336 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/335 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/338 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/673 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/208 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/210 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/207 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/417 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
Musculoskeletal and connective tissue disorders Neck pain	0.30% 1/336 • Number of events 2 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/335 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/338 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/673 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.48% 1/208 • Number of events 2 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/210 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/207 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/417 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
Musculoskeletal and connective tissue disorders Osteitis	0.30% 1/336 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/335 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/338 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/673 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.48% 1/208 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/210 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/207 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/417 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
Musculoskeletal and connective tissue disorders Osteoarthritis	0.89% 3/336 • Number of events 3 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	1.5% 5/335 • Number of events 5 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.89% 3/338 • Number of events 4 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	1.2% 8/673 • Number of events 9 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.96% 2/208 • Number of events 2 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	1.9% 4/210 • Number of events 4 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	1.4% 3/207 • Number of events 4 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	1.7% 7/417 • Number of events 8 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
Musculoskeletal and connective tissue disorders Rotator cuff syndrome	0.30% 1/336 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/335 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/338 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/673 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/208 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/210 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/207 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/417 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
Musculoskeletal and connective tissue disorders Rotator cuff tear arthropathy	0.00% 0/336 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/335 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/338 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/673 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/208 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/210 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.48% 1/207 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.24% 1/417 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
Musculoskeletal and connective tissue disorders Spinal osteoarthritis	0.30% 1/336 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/335 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/338 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/673 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.48% 1/208 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/210 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/207 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/417 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
Musculoskeletal and connective tissue disorders Spinal pain	0.00% 0/336 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.30% 1/335 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/338 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.15% 1/673 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/208 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.48% 1/210 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/207 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.24% 1/417 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
Musculoskeletal and connective tissue disorders Spinal stenosis	0.30% 1/336 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/335 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.30% 1/338 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.15% 1/673 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/208 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/210 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.48% 1/207 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.24% 1/417 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
Musculoskeletal and connective tissue disorders Vertebral foraminal stenosis	0.00% 0/336 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/335 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.30% 1/338 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.15% 1/673 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/208 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/210 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.48% 1/207 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.24% 1/417 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Adenocarcinoma metastatic	0.00% 0/336 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/335 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.30% 1/338 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.15% 1/673 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/208 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/210 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/207 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/417 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Adenocarcinoma of colon	0.00% 0/336 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.30% 1/335 • Number of events 2 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/338 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.15% 1/673 • Number of events 2 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/208 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.48% 1/210 • Number of events 2 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/207 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.24% 1/417 • Number of events 2 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Basal cell carcinoma	0.00% 0/336 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/335 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.30% 1/338 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.15% 1/673 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/208 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/210 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/207 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/417 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Bladder cancer	0.30% 1/336 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/335 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/338 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/673 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.48% 1/208 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/210 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/207 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/417 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Bladder neoplasm	0.89% 3/336 • Number of events 3 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/335 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/338 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/673 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.48% 1/208 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/210 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/207 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/417 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Bone neoplasm	0.00% 0/336 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/335 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.30% 1/338 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.15% 1/673 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/208 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/210 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/207 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/417 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Breast cancer	0.00% 0/336 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.30% 1/335 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/338 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.15% 1/673 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/208 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.48% 1/210 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/207 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.24% 1/417 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Breast cancer recurrent	0.00% 0/336 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.30% 1/335 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/338 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.15% 1/673 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/208 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.48% 1/210 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/207 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.24% 1/417 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Colon cancer	0.00% 0/336 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/335 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.30% 1/338 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.15% 1/673 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/208 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/210 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/207 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/417 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Colon neoplasm	0.00% 0/336 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/335 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/338 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/673 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.48% 1/208 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.48% 1/210 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/207 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.24% 1/417 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Endometrial adenocarcinoma	0.30% 1/336 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/335 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/338 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/673 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.48% 1/208 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/210 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/207 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/417 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Endometrial cancer	0.00% 0/336 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.30% 1/335 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/338 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.15% 1/673 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/208 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.48% 1/210 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/207 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.24% 1/417 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Gastric cancer	0.30% 1/336 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.30% 1/335 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.59% 2/338 • Number of events 2 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.45% 3/673 • Number of events 3 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/208 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.48% 1/210 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	1.4% 3/207 • Number of events 3 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.96% 4/417 • Number of events 4 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Head and neck cancer	0.00% 0/336 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.30% 1/335 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/338 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.15% 1/673 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/208 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/210 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/207 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/417 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Hypopharyngeal cancer	0.30% 1/336 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/335 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/338 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/673 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/208 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/210 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/207 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/417 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Lung carcinoma cell type unspecified stage IV	0.00% 0/336 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.30% 1/335 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/338 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.15% 1/673 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/208 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.48% 1/210 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/207 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.24% 1/417 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Lung neoplasm malignant	0.30% 1/336 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.30% 1/335 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/338 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.15% 1/673 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/208 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/210 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/207 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/417 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Malignant peritoneal neoplasm	0.30% 1/336 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/335 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/338 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/673 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/208 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/210 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/207 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/417 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Metastatic neoplasm	0.00% 0/336 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.30% 1/335 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/338 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.15% 1/673 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/208 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/210 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/207 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/417 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Neoplasm progression	0.00% 0/336 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.30% 1/335 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/338 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.15% 1/673 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/208 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.48% 1/210 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/207 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.24% 1/417 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Non-Hodgkin's lymphoma	0.00% 0/336 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.30% 1/335 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/338 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.15% 1/673 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/208 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/210 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/207 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/417 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Non-small cell lung cancer	0.00% 0/336 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.30% 1/335 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/338 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.15% 1/673 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/208 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/210 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/207 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/417 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Non-small cell lung cancer stage I	0.00% 0/336 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/335 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/338 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/673 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/208 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.48% 1/210 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/207 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.24% 1/417 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Oesophageal carcinoma recurrent	0.00% 0/336 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.30% 1/335 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/338 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.15% 1/673 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/208 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.48% 1/210 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/207 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.24% 1/417 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Pancreatic carcinoma metastatic	0.00% 0/336 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/335 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/338 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/673 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.48% 1/208 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/210 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/207 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/417 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Papillary thyroid cancer	0.00% 0/336 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/335 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.30% 1/338 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.15% 1/673 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/208 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/210 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/207 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/417 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Penile squamous cell carcinoma	0.00% 0/336 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/335 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.30% 1/338 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.15% 1/673 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/208 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/210 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/207 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/417 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Prostate cancer	0.30% 1/336 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.30% 1/335 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/338 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.15% 1/673 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/208 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.95% 2/210 • Number of events 2 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/207 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.48% 2/417 • Number of events 2 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Rectal adenocarcinoma	0.00% 0/336 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/335 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.30% 1/338 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.15% 1/673 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/208 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/210 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/207 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/417 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
Nervous system disorders Basal ganglia infarction	0.00% 0/336 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/335 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/338 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/673 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/208 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.48% 1/210 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/207 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.24% 1/417 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
Nervous system disorders Carotid aneurysm rupture	0.00% 0/336 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.30% 1/335 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/338 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.15% 1/673 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/208 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/210 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/207 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/417 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
Nervous system disorders Carotid arteriosclerosis	0.00% 0/336 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.30% 1/335 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/338 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.15% 1/673 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/208 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.48% 1/210 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/207 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.24% 1/417 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
Nervous system disorders Cerebral haematoma	0.30% 1/336 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/335 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/338 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/673 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/208 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/210 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/207 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/417 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
Nervous system disorders Cerebral infarction	0.60% 2/336 • Number of events 2 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/335 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/338 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/673 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/208 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/210 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/207 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/417 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
Nervous system disorders Cerebrovascular accident	0.60% 2/336 • Number of events 2 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.30% 1/335 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.30% 1/338 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.30% 2/673 • Number of events 2 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.48% 1/208 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/210 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/207 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/417 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
Nervous system disorders Intracranial mass	0.30% 1/336 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/335 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/338 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/673 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/208 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/210 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/207 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/417 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
Nervous system disorders Loss of consciousness	0.00% 0/336 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/335 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.30% 1/338 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.15% 1/673 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/208 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/210 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/207 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/417 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
Nervous system disorders Lumbar radiculopathy	0.30% 1/336 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/335 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/338 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/673 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.48% 1/208 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/210 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/207 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/417 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
Nervous system disorders Parkinson's disease	0.00% 0/336 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.30% 1/335 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/338 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.15% 1/673 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/208 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/210 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/207 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/417 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
Nervous system disorders Radiculopathy	0.00% 0/336 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/335 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.30% 1/338 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.15% 1/673 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/208 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/210 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.48% 1/207 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.24% 1/417 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
Nervous system disorders Sciatica	0.00% 0/336 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.30% 1/335 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/338 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.15% 1/673 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/208 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.48% 1/210 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/207 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.24% 1/417 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
Nervous system disorders Stroke in evolution	0.00% 0/336 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.30% 1/335 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/338 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.15% 1/673 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/208 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/210 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/207 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/417 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
Nervous system disorders Syncope	0.00% 0/336 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.60% 2/335 • Number of events 2 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.30% 1/338 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.45% 3/673 • Number of events 3 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/208 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.48% 1/210 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	1.4% 3/207 • Number of events 3 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.96% 4/417 • Number of events 4 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
Nervous system disorders Transient ischaemic attack	0.00% 0/336 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.30% 1/335 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/338 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.15% 1/673 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/208 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.48% 1/210 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/207 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.24% 1/417 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
Nervous system disorders Vertebrobasilar insufficiency	0.00% 0/336 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/335 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.30% 1/338 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.15% 1/673 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/208 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/210 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/207 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/417 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
Psychiatric disorders Adjustment disorder	0.00% 0/336 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/335 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/338 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/673 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.48% 1/208 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/210 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/207 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/417 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
Renal and urinary disorders Acute kidney injury	0.30% 1/336 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.30% 1/335 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/338 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.15% 1/673 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.48% 1/208 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.48% 1/210 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/207 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.24% 1/417 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
Renal and urinary disorders Bladder stenosis	0.30% 1/336 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/335 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/338 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/673 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/208 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/210 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/207 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/417 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
Renal and urinary disorders Cystitis haemorrhagic	0.30% 1/336 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/335 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/338 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/673 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/208 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/210 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/207 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/417 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
Renal and urinary disorders Renal cyst	0.30% 1/336 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/335 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/338 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/673 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/208 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/210 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/207 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/417 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
Renal and urinary disorders Renal impairment	0.00% 0/336 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.30% 1/335 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/338 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.15% 1/673 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/208 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/210 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/207 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/417 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
Renal and urinary disorders Renal mass	0.30% 1/336 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/335 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/338 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/673 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/208 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/210 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/207 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/417 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
Renal and urinary disorders Ureterolithiasis	0.00% 0/336 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/335 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.30% 1/338 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.15% 1/673 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/208 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/210 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.48% 1/207 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.24% 1/417 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
Reproductive system and breast disorders Benign prostatic hyperplasia	0.00% 0/336 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/335 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/338 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/673 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/208 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/210 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.48% 1/207 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.24% 1/417 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
Reproductive system and breast disorders Cervical dysplasia	0.00% 0/336 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.30% 1/335 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/338 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.15% 1/673 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/208 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.48% 1/210 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/207 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.24% 1/417 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
Reproductive system and breast disorders Prostatitis	0.30% 1/336 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/335 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/338 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/673 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/208 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/210 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/207 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/417 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
Respiratory, thoracic and mediastinal disorders Acute pulmonary oedema	0.00% 0/336 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.30% 1/335 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/338 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.15% 1/673 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/208 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.48% 1/210 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/207 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.24% 1/417 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
Respiratory, thoracic and mediastinal disorders Acute respiratory failure	0.00% 0/336 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.30% 1/335 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/338 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.15% 1/673 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/208 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.48% 1/210 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.48% 1/207 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.48% 2/417 • Number of events 2 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
Respiratory, thoracic and mediastinal disorders Asthma	0.00% 0/336 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.30% 1/335 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/338 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.15% 1/673 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/208 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.48% 1/210 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/207 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.24% 1/417 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
Respiratory, thoracic and mediastinal disorders Chronic obstructive pulmonary disease	0.00% 0/336 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.30% 1/335 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.30% 1/338 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.30% 2/673 • Number of events 2 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/208 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/210 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.48% 1/207 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.24% 1/417 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
Respiratory, thoracic and mediastinal disorders Cough	0.00% 0/336 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.30% 1/335 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/338 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.15% 1/673 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/208 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.48% 1/210 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/207 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.24% 1/417 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
Respiratory, thoracic and mediastinal disorders Cough variant asthma	0.00% 0/336 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/335 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/338 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/673 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/208 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/210 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.48% 1/207 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.24% 1/417 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
Respiratory, thoracic and mediastinal disorders Dyspnoea	0.30% 1/336 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.90% 3/335 • Number of events 3 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/338 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.45% 3/673 • Number of events 3 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.48% 1/208 • Number of events 2 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	1.4% 3/210 • Number of events 3 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/207 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.72% 3/417 • Number of events 3 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
Respiratory, thoracic and mediastinal disorders Epistaxis	0.00% 0/336 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/335 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.30% 1/338 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.15% 1/673 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/208 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/210 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/207 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/417 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
Respiratory, thoracic and mediastinal disorders Nasal cyst	0.00% 0/336 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.30% 1/335 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/338 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.15% 1/673 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/208 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.48% 1/210 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/207 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.24% 1/417 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
Respiratory, thoracic and mediastinal disorders Pleural effusion	0.30% 1/336 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/335 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/338 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/673 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.48% 1/208 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/210 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.48% 1/207 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.24% 1/417 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
Respiratory, thoracic and mediastinal disorders Pleurisy	0.30% 1/336 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/335 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/338 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/673 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.48% 1/208 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/210 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/207 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/417 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
Respiratory, thoracic and mediastinal disorders Pulmonary embolism	0.30% 1/336 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.60% 2/335 • Number of events 2 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.30% 1/338 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.45% 3/673 • Number of events 3 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.48% 1/208 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	1.4% 3/210 • Number of events 3 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.97% 2/207 • Number of events 2 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	1.2% 5/417 • Number of events 5 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
Respiratory, thoracic and mediastinal disorders Pulmonary thrombosis	0.00% 0/336 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/335 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.30% 1/338 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.15% 1/673 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/208 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/210 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/207 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/417 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
Social circumstances Disability	0.00% 0/336 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/335 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.30% 1/338 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.15% 1/673 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/208 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/210 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/207 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/417 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
Surgical and medical procedures Artificial urinary sphincter implant	0.30% 1/336 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/335 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/338 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/673 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/208 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/210 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/207 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/417 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
Surgical and medical procedures Cataract operation	0.00% 0/336 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/335 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/338 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/673 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/208 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.48% 1/210 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/207 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.24% 1/417 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
Surgical and medical procedures Inguinal hernia repair	0.00% 0/336 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/335 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.30% 1/338 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.15% 1/673 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/208 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/210 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/207 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/417 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
Surgical and medical procedures Polypectomy	0.00% 0/336 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/335 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/338 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/673 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/208 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.48% 1/210 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/207 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.24% 1/417 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
Vascular disorders Giant cell arteritis	0.30% 1/336 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/335 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/338 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/673 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.48% 1/208 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/210 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/207 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/417 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
Vascular disorders Hypertension	0.30% 1/336 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.60% 2/335 • Number of events 2 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/338 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.30% 2/673 • Number of events 2 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/208 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/210 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/207 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/417 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
Vascular disorders Hypotension	0.00% 0/336 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.30% 1/335 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/338 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.15% 1/673 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/208 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/210 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/207 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/417 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
Vascular disorders Peripheral arterial occlusive disease	0.00% 0/336 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/335 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/338 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/673 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/208 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.48% 1/210 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/207 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.24% 1/417 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
Vascular disorders Venous thrombosis limb	0.00% 0/336 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.30% 1/335 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/338 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.15% 1/673 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/208 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.48% 1/210 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.00% 0/207 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.24% 1/417 • Number of events 1 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)

Other adverse events

Other adverse events
Measure	Aflibercept 2q8 (Week 0- 96) n=336 participants at risk Participants enrolled in main study received aflibercept 2 mg administered every 8 weeks after 3 initial injections at 4-week intervals.	Aflibercept HDq12 (Week 0- 96) n=335 participants at risk Participants enrolled in main study received high dose (HD) aflibercept administered every 12 weeks after 3 initial injections at 4-week intervals. Participants in this group could have their treatment intervals adjusted according to pre-specified dose regimen modification (DRM) criteria.	Aflibercept HDq16 (Week 0- 96) n=338 participants at risk Participants enrolled in main study received high dose (HD) aflibercept administered every 16 weeks after 3 initial injections at 4-week intervals. Participants in this group could have their treatment intervals adjusted according to pre-specified dose regimen modification (DRM) criteria.	All Aflibercept HD (Week 0- 96) n=673 participants at risk All participants from aflibercept HDq12 (Week 0-96) and aflibercept HDq16 (Week 0-96).	Aflibercept 2q8/HD (Week 0- 156) n=208 participants at risk Participants enrolled in the extension originally assigned to 2q8 in main study and switched to high dose aflibercept every 12 weeks starting at Week 96. Participants in this group could have their treatment intervals adjusted in the extension according to pre-specified dose regimen modification (E-DRM) criteria.	Aflibercept HDq12 (Week 0- 156) n=210 participants at risk Participants enrolled in the extension originally assigned to HDq12 in main study and continued with HD aflibercept at their latest dosing interval at Week 96. Participants in this group could have their treatment intervals adjusted in the extension according to pre-specified dose regimen modification (E-DRM) criteria.	Aflibercept HDq16 (Week 0- 156) n=207 participants at risk Participants enrolled in the extension originally assigned to HDq16 in main study and continued with HD aflibercept at their latest dosing interval at Week 96. Participants in this group could have their treatment intervals adjusted in the extension according to pre-specified dose regimen modification (E-DRM) criteria.	All Aflibercept HD (Week 0- 156) n=417 participants at risk All participants from aflibercept HDq12 (Week 0-156) and aflibercept HDq16 (Week 0-156). Participants in this group could have their treatment intervals adjusted in the extension according to pre-specified dose regimen modification (E-DRM) criteria.
Eye disorders Cataract	6.5% 22/336 • Number of events 22 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	8.7% 29/335 • Number of events 29 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	9.5% 32/338 • Number of events 33 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	9.1% 61/673 • Number of events 62 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	13.0% 27/208 • Number of events 29 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	16.2% 34/210 • Number of events 37 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	15.9% 33/207 • Number of events 35 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	16.1% 67/417 • Number of events 72 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
Eye disorders Retinal haemorrhage	5.7% 19/336 • Number of events 21 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	4.8% 16/335 • Number of events 16 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	5.0% 17/338 • Number of events 20 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	4.9% 33/673 • Number of events 36 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	8.2% 17/208 • Number of events 22 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	5.2% 11/210 • Number of events 11 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	5.3% 11/207 • Number of events 15 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	5.3% 22/417 • Number of events 26 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
Eye disorders Visual acuity reduced	7.1% 24/336 • Number of events 31 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	6.3% 21/335 • Number of events 24 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	6.8% 23/338 • Number of events 34 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	6.5% 44/673 • Number of events 58 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	7.7% 16/208 • Number of events 23 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	7.1% 15/210 • Number of events 17 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	6.8% 14/207 • Number of events 16 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	7.0% 29/417 • Number of events 33 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
Eye disorders Vitreous floaters	4.8% 16/336 • Number of events 17 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	1.5% 5/335 • Number of events 6 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	5.0% 17/338 • Number of events 19 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	3.3% 22/673 • Number of events 25 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	5.8% 12/208 • Number of events 13 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	0.95% 2/210 • Number of events 2 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	8.7% 18/207 • Number of events 20 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	4.8% 20/417 • Number of events 22 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
Infections and infestations Bronchitis	3.0% 10/336 • Number of events 11 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	2.4% 8/335 • Number of events 8 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	1.2% 4/338 • Number of events 4 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	1.8% 12/673 • Number of events 12 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	5.3% 11/208 • Number of events 11 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	3.3% 7/210 • Number of events 8 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	2.9% 6/207 • Number of events 7 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	3.1% 13/417 • Number of events 15 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
Infections and infestations COVID-19	17.9% 60/336 • Number of events 64 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	17.3% 58/335 • Number of events 59 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	20.7% 70/338 • Number of events 73 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	19.0% 128/673 • Number of events 132 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	24.0% 50/208 • Number of events 59 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	21.0% 44/210 • Number of events 45 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	28.5% 59/207 • Number of events 62 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	24.7% 103/417 • Number of events 107 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
Infections and infestations Nasopharyngitis	8.9% 30/336 • Number of events 40 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	5.4% 18/335 • Number of events 25 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	8.0% 27/338 • Number of events 31 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	6.7% 45/673 • Number of events 56 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	13.5% 28/208 • Number of events 46 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	9.5% 20/210 • Number of events 33 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	13.5% 28/207 • Number of events 38 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	11.5% 48/417 • Number of events 71 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
Infections and infestations Urinary tract infection	5.4% 18/336 • Number of events 20 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	3.6% 12/335 • Number of events 12 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	4.1% 14/338 • Number of events 19 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	3.9% 26/673 • Number of events 31 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	8.2% 17/208 • Number of events 20 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	5.2% 11/210 • Number of events 11 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	6.8% 14/207 • Number of events 20 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	6.0% 25/417 • Number of events 31 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
Investigations Intraocular pressure increased	3.0% 10/336 • Number of events 19 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	3.6% 12/335 • Number of events 20 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	3.3% 11/338 • Number of events 20 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	3.4% 23/673 • Number of events 40 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	3.8% 8/208 • Number of events 20 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	5.7% 12/210 • Number of events 21 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	3.9% 8/207 • Number of events 12 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	4.8% 20/417 • Number of events 33 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
Musculoskeletal and connective tissue disorders Arthralgia	2.4% 8/336 • Number of events 10 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	3.6% 12/335 • Number of events 13 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	3.3% 11/338 • Number of events 12 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	3.4% 23/673 • Number of events 25 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	3.4% 7/208 • Number of events 9 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	2.9% 6/210 • Number of events 7 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	6.8% 14/207 • Number of events 15 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	4.8% 20/417 • Number of events 22 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
Musculoskeletal and connective tissue disorders Back pain	6.2% 21/336 • Number of events 31 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	5.1% 17/335 • Number of events 27 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	4.1% 14/338 • Number of events 15 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	4.6% 31/673 • Number of events 42 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	6.7% 14/208 • Number of events 24 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	5.2% 11/210 • Number of events 24 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	6.8% 14/207 • Number of events 15 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	6.0% 25/417 • Number of events 39 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
Respiratory, thoracic and mediastinal disorders Cough	3.0% 10/336 • Number of events 13 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	2.4% 8/335 • Number of events 8 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	3.8% 13/338 • Number of events 14 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	3.1% 21/673 • Number of events 22 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	7.2% 15/208 • Number of events 22 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	2.9% 6/210 • Number of events 6 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	5.8% 12/207 • Number of events 16 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	4.3% 18/417 • Number of events 22 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)
Vascular disorders Hypertension	5.4% 18/336 • Number of events 21 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	6.6% 22/335 • Number of events 26 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	6.8% 23/338 • Number of events 23 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	6.7% 45/673 • Number of events 49 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	8.7% 18/208 • Number of events 20 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	10.0% 21/210 • Number of events 25 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	7.2% 15/207 • Number of events 15 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)	8.6% 36/417 • Number of events 40 • Through Week 96, from first dosing up to 30 days after last dosing (active or sham procedure). Through Week 156, from first dosing up to 30 days after last dosing (active or sham procedure) or the Week 156 visit, whichever was later. AE reporting for all-cause mortality considers all deaths occurred at any time during the study before the last contact. Ocular TEAEs in study eye and non-ocular TEAEs (ocular TEAEs in fellow eye are excluded)

Additional Information

Therapeutic Area Head

Bayer

Phone: (+) 1-888-8422937

Email: [email protected]

Results disclosure agreements

Principal investigator is a sponsor employee
Publication restrictions are in place

Restriction type: LTE60